Report Company Directory

Exactus Inc

• Solar – Hold: Slowdown in Industry and, to a lesser extent, Installation triggers major P/W ahead of Q2 by Nordea
• Solar – Hold: We expect somewhat lower momentum in Q2 by Nordea
• Exactus, Inc. Reports Second Quarter 2020 Financial Results and Conference Call by GlobeNewsWire
• Exactus, Inc. Reports First Quarter 2020 Financial Results by GlobeNewsWire
• Exactus Appoints Leading Business Expert, Julian Pittam to Chairman of the Board of Directors by GlobeNewsWire
• Exactus Announces its Hemp Seed Buyback Program to Assist Farmers Impacted by the COVID-19 Pandemic by GlobeNewsWire
• Exactus, Inc. Reports 2019 Year End Results by GlobeNewsWire
• Exactus Appoints Technology Expert Mark Alouf to Its Advisory Board by GlobeNewsWire
• Exactus Announces the Promotion of Derek Du Chesne as Company President and appointment to the Board of Directors by GlobeNewsWire
• Exactus Appoints Co-Founder of Rokt Justin Viles to its Board of Directors by GlobeNewsWire

Exagen

• Exagen Inc. to Participate in Third Quarter Investor Conferences by GlobeNewsWire
• Exagen Inc. Reports Strong Q2 2025 Results by GlobeNewsWire
• Exagen Inc. Appoints Chas McKhann to Board of Directors by GlobeNewsWire
• Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 by GlobeNewsWire
• Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics by GlobeNewsWire
• Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares by GlobeNewsWire
• Exagen Inc. Prices Public Offering of Common Stock by GlobeNewsWire
• Exagen Inc. Announces Proposed Public Offering of Common Stock by GlobeNewsWire
• Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume by GlobeNewsWire
• Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors by GlobeNewsWire

Exalenz Bioscience

• Exalenz Announces Third Quarter 2018 Financial Results by GlobeNewsWire
• Exalenz to Present Positive Clinical Data for the Breath ID® 13C-Methacetin Breath Test System at the Liver Meeting® 2018 by GlobeNewsWire
• Exalenz Announces Second Quarter 2018 Financial Results by GlobeNewsWire
• Exalenz Bioscience’s Non-Invasive BreathID® Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH by GlobeNewsWire
• Exalenz Announces Confidential Submission of Draft Registration Statement for Initial Public Offering by GlobeNewsWire
• Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients by GlobeNewsWire

ExamWorks Group Inc

Exantas Capital Corp

• Raymond James Morning Notes - ABST, CHUY, CRNC, CSCO, FIS, FTAI, HQY, IIIV, LEG, MBUU, NRZ, PAA, PLAY, RPD, RRGB, WCC by Raymond James
• Mortgage REITs | Short Interest Tracker: January 2021 by Raymond James
• Raymond James Morning Notes - AAPL, ABT, AVT, CASH, FB, FMBI, NOW, PFC, SYK, UMBF, ZYME by Raymond James
• Mortgage REITs | Short Interest Tracker: Mid-January 2021 by Raymond James
• Raymond James Morning Notes - CWST, SCM, WCC by Raymond James
• Mortgage REITs | Short Interest Tracker: December 2020 by Raymond James
• Raymond James Morning Notes - AVTR, CEQP, DEA, DEI, DRH, EPRT, FCPT, HLT, HST, MGP, PRMW, RHP, SBNY, SNX, SRC, STOR, TRGP, XHR, ZYME by Raymond James
• Real Estate | 2021 Outlook: Hoping 2021 Vision is Sharper than 2020 by Raymond James
• Raymond James Afternoon Notes by Raymond James
• Mortgage REITs | Short Interest Tracker: Mid-December 2020 by Raymond James